Key Points
- Director Luke Evnin sold 36,726 shares on Dec. 3 at an average $0.87 for $31,951.62, leaving him with 3,121,694 shares (a ~1.16% drop in his ownership, valued at about $2.72M).
- Evnin conducted multiple insider sales from Nov. 19–Dec. 4 — 11 trades in total — totaling approximately $384,200, indicating sustained selling over the period.
- Werewolf Therapeutics shares were trading around $0.98 with a market cap of about $47.7M, while analysts' average target is roughly $7.75 (consensus rating: Moderate Buy), highlighting a large gap between current price and analyst expectations.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 36,726 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $0.87, for a total transaction of $31,951.62. Following the completion of the transaction, the director directly owned 3,121,694 shares in the company, valued at approximately $2,715,873.78. This represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Luke Evnin also recently made the following trade(s):
- On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $51,813.52.
- On Tuesday, December 2nd, Luke Evnin sold 38,043 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $33,858.27.
- On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $36,750.24.
- On Friday, November 28th, Luke Evnin sold 13,014 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total value of $12,883.86.
- On Wednesday, November 26th, Luke Evnin sold 38,978 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $38,198.44.
- On Tuesday, November 25th, Luke Evnin sold 27,297 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total value of $25,113.24.
- On Monday, November 24th, Luke Evnin sold 56,992 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $55,852.16.
- On Friday, November 21st, Luke Evnin sold 41,287 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total transaction of $34,268.21.
- On Thursday, November 20th, Luke Evnin sold 26,411 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total transaction of $23,505.79.
- On Wednesday, November 19th, Luke Evnin sold 42,566 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $40,012.04.
Werewolf Therapeutics Stock Performance
Werewolf Therapeutics stock traded down $0.01 during midday trading on Friday, hitting $0.98. The company's stock had a trading volume of 67,889 shares, compared to its average volume of 502,483. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. The company has a market cap of $47.67 million, a price-to-earnings ratio of -0.61 and a beta of 0.74. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38. The company has a 50-day moving average price of $1.40 and a two-hundred day moving average price of $1.33.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. As a group, sell-side analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of HOWL. Charles Schwab Investment Management Inc. lifted its holdings in shares of Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company's stock worth $93,000 after acquiring an additional 23,852 shares during the last quarter. Nuveen LLC bought a new stake in shares of Werewolf Therapeutics during the 1st quarter valued at approximately $71,000. MPM Asset Management LLC increased its position in Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company's stock worth $4,189,000 after purchasing an additional 25,688 shares in the last quarter. MPM Bioimpact LLC lifted its stake in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company's stock valued at $2,341,000 after purchasing an additional 20,799 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in Werewolf Therapeutics in the 1st quarter valued at approximately $79,000. Institutional investors and hedge funds own 64.84% of the company's stock.
Analyst Upgrades and Downgrades
HOWL has been the subject of several analyst reports. Bank of America dropped their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday, November 18th. Citigroup restated a "market outperform" rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. JMP Securities cut their price objective on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating for the company in a research report on Thursday, August 21st. Zacks Research lowered shares of Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, November 21st. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Werewolf Therapeutics has an average rating of "Moderate Buy" and an average target price of $7.75.
Get Our Latest Research Report on Werewolf Therapeutics
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
